40.65
1.00 (2.52%)
| Penutupan Terdahulu | 39.65 |
| Buka | 39.68 |
| Jumlah Dagangan | 5,400,130 |
| Purata Dagangan (3B) | 3,739,896 |
| Modal Pasaran | 23,706,034,176 |
| Harga / Pendapatan (P/E TTM) | 23.23 |
| Harga / Pendapatan (P/E Ke hadapan) | 11.51 |
| Harga / Jualan (P/S) | 9.47 |
| Harga / Buku (P/B) | 2.59 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Hasil Dividen (DY TTM) | 2.17% |
| Margin Keuntungan | 48.26% |
| Margin Operasi (TTM) | 94.00% |
| EPS Cair (TTM) | 2.45 |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 4,888.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 77.82% |
| Nisbah Semasa (MRQ) | 1.56 |
| Aliran Tunai Operasi (OCF TTM) | 2.70 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -1.36 B |
| Pulangan Atas Aset (ROA TTM) | 7.04% |
| Pulangan Atas Ekuiti (ROE TTM) | 18.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Royalty Pharma plc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.10 |
|
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Value |
| % Dimiliki oleh Orang Dalam | 8.92% |
| % Dimiliki oleh Institusi | 79.64% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Caledonia (Private) Investments Pty Ltd | 30 Sep 2025 | 7,547,609 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 54.00 (Morgan Stanley, 32.84%) | Beli |
| Median | 49.50 (21.77%) | |
| Rendah | 45.00 (TD Cowen, 10.70%) | Beli |
| Purata | 49.50 (21.77%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 37.41 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| TD Cowen | 11 Dec 2025 | 45.00 (10.70%) | Beli | 38.81 |
| Morgan Stanley | 10 Oct 2025 | 54.00 (32.84%) | Beli | 36.01 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BASSLER BONNIE L | 38.64 | - | 967 | 37,365 |
| URIST MARSHALL | - | 39.22 | -20,000 | -784,400 |
| Jumlah Keseluruhan Kuantiti Bersih | -19,033 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -747,035 | |||
| Purata Pembelian Keseluruhan ($) | 38.64 | |||
| Purata Jualan Keseluruhan ($) | 39.22 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BASSLER BONNIE L | Pengarah | 31 Dec 2025 | Diperolehi (+) | 967 | 38.64 | 37,365 |
| URIST MARSHALL | Pegawai | 26 Dec 2025 | Jual automatik (-) | 20,000 | 39.22 | 784,400 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Dec 2025 | Pengumuman | Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones |
| 16 Dec 2025 | Pengumuman | Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million |
| 04 Dec 2025 | Pengumuman | Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement |
| 04 Dec 2025 | Pengumuman | Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement |
| 26 Nov 2025 | Pengumuman | Royalty Pharma to Present at Upcoming Investor Conferences |
| 05 Nov 2025 | Pengumuman | Royalty Pharma Reports Third Quarter 2025 Results |
| 04 Nov 2025 | Pengumuman | Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences |
| 17 Oct 2025 | Pengumuman | Royalty Pharma Declares Fourth Quarter 2025 Dividend |
| 09 Oct 2025 | Pengumuman | Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 |
| Hasil Dividen (DY TTM) | 2.17% |
| Purata Hasil Dividen 5T | 2.41% |
| Nisbah Pembayaran | 34.69% |
| Jangkaan Pembayaran Dividen Seterusnya | Jun 2026 |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 14 Nov 2025 | 17 Oct 2025 | 10 Dec 2025 | 0.22 Tunai |
| 15 Aug 2025 | 18 Jul 2025 | 10 Sep 2025 | 0.22 Tunai |
| 16 May 2025 | 21 Apr 2025 | 10 Jun 2025 | 0.22 Tunai |
| 21 Feb 2025 | 09 Jan 2025 | 10 Mar 2025 | 0.22 Tunai |
| 15 Nov 2024 | 11 Oct 2024 | 10 Dec 2024 | 0.21 Tunai |
| 16 Aug 2024 | 17 Jul 2024 | 13 Sep 2024 | 0.21 Tunai |
| 16 May 2024 | 17 Apr 2024 | 14 Jun 2024 | 0.21 Tunai |
| 15 Feb 2024 | 19 Jan 2024 | 15 Mar 2024 | 0.21 Tunai |
| 16 Nov 2023 | 16 Oct 2023 | 15 Dec 2023 | 0.2 Tunai |
| 17 Aug 2023 | 17 Jul 2023 | 15 Sep 2023 | 0.2 Tunai |
| 18 May 2023 | 17 Apr 2023 | 15 Jun 2023 | 0.2 Tunai |
| 15 Feb 2023 | 09 Jan 2023 | 15 Mar 2023 | 0.2 Tunai |
| 17 Nov 2022 | 17 Oct 2022 | 15 Dec 2022 | 0.19 Tunai |
| 18 Aug 2022 | - | 15 Sep 2022 | 0.19 Tunai |
| 19 May 2022 | 18 Apr 2022 | 15 Jun 2022 | 0.19 Tunai |
| 17 Feb 2022 | 06 Jan 2022 | 15 Mar 2022 | 0.19 Tunai |
| 18 Nov 2021 | 15 Oct 2021 | 15 Dec 2021 | 0.17 Tunai |
| 19 Aug 2021 | 16 Jul 2021 | 15 Sep 2021 | 0.17 Tunai |
| 19 May 2021 | 15 Apr 2021 | 15 Jun 2021 | 0.17 Tunai |
| 18 Feb 2021 | 08 Jan 2021 | 15 Mar 2021 | 0.17 Tunai |
| 19 Nov 2020 | 15 Oct 2020 | 15 Dec 2020 | 0.15 Tunai |
| 14 Sep 2020 | 02 Sep 2020 | 30 Sep 2020 | 0.15 Tunai |
| Papar semua | |||
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2025 | 0.880 | 4 | 2.28 |
| 2024 | 0.840 | 4 | 3.29 |
| 2023 | 0.800 | 4 | 2.85 |
| 2022 | 0.760 | 4 | 1.92 |
| 2021 | 0.680 | 4 | 1.71 |
| 2020 | 0.300 | 2 | 0.60 |
| Papar semua | |||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |